Myasthenia Gravis crossing Parkinson’s disease: a 20 year study from single Italian center

References

• Gilhus NE, Skeie GO, Romi F, et al. Myasthenia Gravis - autoantibody characteristics and their implications for therapy. Nat Rev Neurol. 2016;12(5):259–268.
   PubMed Web of Science ®Google Scholar
• Jaretzki A, 3rd, Barohn RJ, Ernstoff RM, et al. Myasthenia Gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the Myasthenia Gravis foundation of america. Neurology. 2000;5:16–23.
   Google Scholar
• Yildiz Celik S, Durmus H, Yilmaz V, et al. Late-onset generalized Myasthenia Gravis: clinical features, treatment, and outcome. Acta Neurol Belg. 2020;120(1):133–140.
   PubMed Web of Science ®Google Scholar
• Goetz CG, Poewe W, Rascol O, et al. Movement disorder society task force report on the hoehn and yahr staging scale: status and recommendations. Mov Disord. 2004;19(9):1020–1028.
   PubMed Web of Science ®Google Scholar
• Jankovic J, Tan EK. Parkinson's disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2020;91(8):795–808.
   PubMed Web of Science ®Google Scholar
• Vizcarra JA, Lang AE, Sethi KD, et al. Vascular Parkinsonism: deconstructing a syndrome. Mov Disord. 2015;30(7):886–894.
   PubMed Web of Science ®Google Scholar
• Hayes MT. Parkinson's disease and Parkinsonism. Am J Med. 2019;132(7):802–807.
   PubMed Web of Science ®Google Scholar
• Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. JAMA. 2020;323(6):548–560.
   PubMed Web of Science ®Google Scholar
• Ueno S, Takahashi M, Kajiyama K, et al. Parkinson’s disease and Myasthenia Gravis: adverse effect of trihexyphenidyl on neuromuscular transmission. Neurology. 1987;37(5):832–833.
   PubMed Web of Science ®Google Scholar
• Odajiu I, Davidescu EI, Mitu C, et al. Patients with Parkinson's disease and Myasthenia Gravis-A report of three new cases and review of the literature. Medicina (Kaunas). 2019;56(1):5.
   PubMed Web of Science ®Google Scholar
• Fasano A, Evoli A, Piano C, et al. Myasthenia Gravis: an unrecognized cause of head drop in Parkinson's disease. Parkinsonism Relat Disord. 2008;14(2):164–165.
   PubMed Web of Science ®Google Scholar
• Zis P, Argiriadou V, Temperikidis PP, et al. Parkinson's disease associated with Myasthenia Gravis and rheumatoid arthritis. Neurol Sci. 2014;35(5):797–799.
   PubMed Web of Science ®Google Scholar
• Tung-Chen Y, Bataller L, Sevilla T, et al. Co-ocurrence of Myasthenia Gravis with Parkinson’s disease: a not to be missed diagnosis. Geriatr Gerontol Int. 2016;16(4):528–530.
   PubMed Web of Science ®Google Scholar
• Marano M, Lanzone J, di Biase L, et al. A rare cause of axial worsening in Parkinson's disease: a case of myasthenic pseudo-Parkinsonism. Clin Neurol Neurosurg. 2019;179:1–3.
   PubMed Web of Science ®Google Scholar
• Neuman LA, Cheema FZ. Two cases of Parkinson disease and concurrent Myasthenia Gravis, generalized and ocular. Neurohospitalist. 2014;4(3):117–118.
   PubMedGoogle Scholar
• Kao KP, Kwan SY, Lin KP, et al. Coexistence of Parkinson’s disease and Myasthenia Gravis: a case report. Clin Neurol Neurosurg. 1993;95(2):137–139.
   PubMed Web of Science ®Google Scholar
• Levin N, Karussis D, Abramsky O. Parkinson’s disease associated with Myasthenia Gravis. A report of 4 cases. J Neurol. 2003;250(6):766–767.
   PubMed Web of Science ®Google Scholar
• Albassam MS, Thabet SA, Hmoud M, et al. Anti-Muscle specific kinase (Anti-MuSK) positive Myasthenia Gravis overlapping With Parkinson's disease: a challenging diagnosis. Cureus. 2021;13(5):e14839.
   PubMed Web of Science ®Google Scholar
• Hogg EJ, Lewis RA, Bannykh S, et al. Head drop in Parkinson's disease complicated by Myasthenia Gravis and myopathy. J Neurol Sci. 2017;376:216–218.
   PubMed Web of Science ®Google Scholar
• Alshaikh JT, Mills K. Coincident Parkinsonism and Myasthenia Gravis: a case series. Parkinsonism Relat Disord. 2021;89:4–5.
   PubMed Web of Science ®Google Scholar
• Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015;30(12):1591–1601.
   PubMed Web of Science ®Google Scholar
• Markowiak T, Hofmann HS, Ried M. Classification and staging of thymoma. J Thorac Dis. 2020;12(12):7607–7612.
   PubMed Web of Science ®Google Scholar
• Lee SY, Gill A, Jung SM. Pure red cell aplasia and seronegative Myasthenia Gravis in association with thymoma. J Community Hosp Intern Med Perspect. 2020;10(3):238–241.
   PubMed Web of Science ®Google Scholar
• Lo Iacono G, Gigli F, Gherzi L, et al. Thymoma and pure red cell aplasia with hypoplasia of megakaryocytopoiesis: a rare and life-treating condition. Transfus Apher Sci. 2020;59(2):102656.
   PubMed Web of Science ®Google Scholar
• Moriyama S, Yano M, Haneda H, et al. Pure red cell aplasia associated with thymoma: a report of a single-center experience. J Thorac Dis. 2018;10(8):5066–5072.
   PubMed Web of Science ®Google Scholar
• Thompson CA, Steensma DP. Pure red cell aplasia associated with thymoma: clinical insights from a 50-year single-institution experience. Br J Haematol. 2006;135(3):405–407.
   PubMed Web of Science ®Google Scholar
• Masuda M, Arai Y, Okamura T, et al. Pure red cell aplasia with thymona: evidence of T-cell clonal disorder. Am J Hematol. 1997;54(4):324–328.
   PubMed Web of Science ®Google Scholar
• Kohler S, Keil T, Alexander T, et al. Altered naive CD4+ T cell homeostasis in Myasthenia Gravis and thymoma patients. J Neuroimmunol. 2019;327:10–14.
   PubMed Web of Science ®Google Scholar
• Cortés-Vicente E, Álvarez-Velasco R, Segovia S, et al. Clinical and therapeutic features of Myasthenia Gravis in adults based on age at onset. Neurology. 2020;94(11):e1171–e1180.
   PubMed Web of Science ®Google Scholar
• Melzer N, Ruck T, Gold R, et al. Clinical features, pathogenesis, and treatment of Myasthenia Gravis: a supplement to the guidelines of the german neurological society. J Neurol. 2016;263(8):1473–1494.
   PubMed Web of Science ®Google Scholar
• Nielsen JC, Lin Y-J, de Oliveira Figueiredo MJ, et al. Heart rhythm association (EHRA)/heart rhythm society (HRS)/asia pacific heart rhythm society (APHRS)/latin American heart rhythm society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. J Arrhythm. 2020;36(4):553–607.
   PubMed Web of Science ®Google Scholar
• Balestrino R, Schapira AHV. Parkinson disease. Eur J Neurol. 2020;27(1):27–42.
   PubMed Web of Science ®Google Scholar
• Bellou V, Belbasis L, Tzoulaki I, et al. Environmental risk factors and Parkinson's disease: an umbrella review of meta-analyses. Parkinsonism Relat Disord. 2016;23:1–9.
   PubMed Web of Science ®Google Scholar
• Tolosa E, Garrido A, Scholz SW, et al. Challenges in the diagnosis of Parkinson's disease. Lancet Neurol. 2021;20(5):385–397.
   PubMed Web of Science ®Google Scholar
• Chen J, Cao X, Xu Y, et al. Experimental study of serum substantia nigra neuron autoantibody and its effect in Parkinson disease patients. J Tongji Med Univ. 2001;21(4):280–282.
   PubMedGoogle Scholar
• Koutsilieri E, Lutz MB, Scheller C. Autoimmunity, dendritic cells and relevance for Parkinson's disease. J Neural Transm (Vienna). 2013;120(1):75–81.
   PubMed Web of Science ®Google Scholar
• Marogianni C, Sokratous M, Dardiotis E, et al. Neurodegeneration and inflammation-an interesting interplay in Parkinson's disease. IJMS. 2020;21(22):8421.
   Web of Science ®Google Scholar
• Riccò M, Vezzosi L, Balzarini F, et al. Prevalence of Parkinson disease in Italy: a systematic review and meta-analysis. Acta Biomed. 2020;91(3):e2020088.
   PubMedGoogle Scholar